OAM
TRAW icon

Oxford Asset Management’s Traws Pharma TRAW Stock Holding History

Oxford Asset Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-40
Closed -$32K – 2038
2018
Q4 		$32K Buy
+40
New +$68.2K ﹤0.01% 1727

Other funds holding TRAW

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Oxford Asset Management's TRAW Position: Q1 2019 in Review

Oxford Asset Management sold out of Traws Pharma (TRAW) in Q1 2019, closing a stake of 40 shares — an estimated $32K sold.

Oxford Asset Management first reported a position in TRAW in Q4 2018 and held it in 1 quarter. The position peaked at $32K in Q4 2018. 12 funds tracked by Wall St. Rank hold TRAW as of Q1 2019.

  • Oxford Asset Management reported no remaining Traws Pharma position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 40 Traws Pharma shares in Q1 2019, an estimated $32K.
  • Oxford Asset Management first reported a position in Traws Pharma in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's Traws Pharma position peaked at $32K in Q4 2018.
  • 12 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.